ArticleFrontiers in immunology2026
Potential association between IL-17A inhibition and blood pressure reduction in patients with axial spondyloarthritis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate longitudinal changes in blood pressure associated with IL-17A inhibition in patients with axial spondyloarthritis (ax-SpA). Methods: This was a single-center, prospective, single-arm exploratory study that included 50 axSpA patients who received the IL-17A inhibitor Ixekizumab (160 mg loading dose at week 0, followed by 80 mg every 4 weeks for 12 weeks). Disease activity (ASDAS-CRP, ASDAS-ESR, BASDAI), inflammatory markers (CRP, ESR, IL-6), and blood pressure were monitored at baseline and every 4 weeks after treatment initiation. A linear mixed-effects model was used to analyze longitudinal changes in blood pressure. Results: IL-17A inhibition significantly improved disease activity and reduced inflammatory marker levels (all Conclusion: In this exploratory pilot study, IL-17A inhibition was associated with effective control of disease activity and a concomitant, time-dependent reduction in blood pressure in patients with ax-SpA. Linear mixed-model analysis suggested this reduction was particularly evident for DBP in patients with baseline hypertension. These findings provide preliminary clinical evidence supporting further investigation into the potential cardiovascular modulatory effects of IL-17A-targeted therapy. However, the uncontrolled design necessitates confirmation in randomized trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.